Overview - BioMarin experienced a successful 2025 and is looking forward to an exciting 2026 [1] Financial Performance - Total revenue for BioMarin grew by 13% in 2025, driven by a 26% increase in revenue from VOXZOGO and a 9% growth from the Enzyme Therapies business unit [2] - The company has been on a profitability improvement journey, with earnings per share growing at a rate greater than revenue for several consecutive quarters, including in 2025 [2] - After adjusting for special items affecting earnings in 2025, BioMarin achieved more than 2x leverage on earnings [2]

Fourth Quarter and Full Year 2025 Earnings Q4'25 and FY'25 Earnings Agenda: Alexander Hardy Chief Executive Officer Brian Mueller Chief Financial Officer Cristin Hubbard Chief Commercial Officer February 23, 2026 Forward-Looking Statements This presentation and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expect ...